EPRX
Eupraxia Pharmaceuticals Inc

140
Mkt Cap
$324.15M
Volume
30,287.00
52W High
$7.19
52W Low
$2.68
PE Ratio
-7.37
EPRX Fundamentals
Price
$6.28
Prev Close
$6.40
Open
$6.28
50D MA
$5.97
Beta
0.49
Avg. Volume
173,654.63
EPS (Annual)
-$0.7516
P/B
5.55
Loading...
Loading...
News
all
press releases
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Upgraded to "Strong-Buy" at Lifesci Capital
Lifesci Capital raised shares of Eupraxia Pharmaceuticals to a "strong-buy" rating in a research note on Thursday...
MarketBeat·7h ago
News Placeholder
More News
News Placeholder
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Rating of "Moderate Buy" by Brokerages
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six research firms that are currently covering the firm...
MarketBeat·15d ago
News Placeholder
Wall Street Zen Downgrades Eupraxia Pharmaceuticals (NASDAQ:EPRX) to Sell
Wall Street Zen cut Eupraxia Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Sunday...
MarketBeat·19d ago
News Placeholder
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Upgraded at Wall Street Zen
Wall Street Zen raised shares of Eupraxia Pharmaceuticals to a "hold" rating in a report on Saturday...
MarketBeat·26d ago
News Placeholder
FY2025 Earnings Forecast for EPRX Issued By HC Wainwright
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Free Report) - Research analysts at HC Wainwright boosted their FY2025 earnings estimates for Eupraxia Pharmaceuticals in a note issued to investors on...
MarketBeat·27d ago
News Placeholder
Wall Street Analysts Think Eupraxia Pharmaceuticals Inc. (EPRX) Could Surge 75.08%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 75.1% in Eupraxia Pharmaceuticals Inc. (EPRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·28d ago
News Placeholder
Is Elanco Animal Health (ELAN) Stock Outpacing Its Medical Peers This Year?
Here is how Elanco Animal Health Incorporated (ELAN) and Eupraxia Pharmaceuticals Inc. (EPRX) have performed compared to their sector so far this year.
Zacks·2mo ago
News Placeholder
Eupraxia Pharmaceuticals Inc. (EPRX) is a Great Momentum Stock: Should You Buy?
Does Eupraxia Pharmaceuticals Inc. (EPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·2mo ago
News Placeholder
Eupraxia Pharmaceuticals Inc. (EPRX) Upgraded to Buy: Here's Why
Eupraxia Pharmaceuticals Inc. (EPRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·2mo ago
News Placeholder
Wall Street Analysts Believe Eupraxia Pharmaceuticals Inc. (EPRX) Could Rally 85.12%: Here's is How to Trade
The consensus price target hints at an 85.1% upside potential for Eupraxia Pharmaceuticals Inc. (EPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·2mo ago

Latest EPRX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.